Leading brokers name 3 ASX shares to buy today

Here's why brokers rate these ASX shares as buys…

| More on:
ASX shares Business man marking buy on board and underlining it

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

Appen Ltd (ASX: APX)

According to a note out of Citi, its analysts have retained their buy rating and $9.15 price target on this artificial intelligence data services company's shares. This follows an update out of Meta (Facebook), which revealed an increase in artificial intelligence and machine learning investment. Citi feels this bodes well for Appen given how Facebook is one of the company's biggest customers. The Appen share price is trading at $6.39 on Monday afternoon.

Coles Group Ltd (ASX: COL)

A note out of Morgans reveals that its analysts have retained their add rating and lifted their price target on this supermarket giant's shares to $20.65. Morgans highlights that Coles delivered a third quarter sales update slightly ahead of its estimates. It feels this was a big positive given the major disruptions during the period. Overall, the broker continues to see Coles as a good value option with defensive qualities and the capacity to invest in growth opportunities. The Coles share price is fetching $18.52 today.

ResMed Inc (ASX: RMD)

Analysts at Goldman Sachs have retained their buy rating but trimmed their price target on this sleep treatment company's shares to $33.70. Goldman notes that ResMed's quarterly update highlighted that supply chain pressures remain acute and the near-term upside from the key competitor recall remains more limited than hoped. Nevertheless, the broker believes ResMed is still in a stronger position today than 12 months ago and does not believe the near term challenges should be overcapitalised. The ResMed share price is trading at $28.63 on Monday.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Appen Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended COLESGROUP DEF SET. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Man smiling at a laptop because of a rising share price.
Broker Notes

4 ASX shares to buy this week: experts

Looking for investment inspiration?

Read more »

Excited couple celebrating success while looking at smartphone.
Broker Notes

Macquarie forecasts 28% upside for this ASX All Ords stock

Let's see why the broker is feeling bullish about this name.

Read more »

A share market analyst looks at his computer screen in front of him showing ASX share price movements
Broker Notes

What's Macquarie focused on this earnings season?

Here's what the broker is saying about next month's results releases.

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

Should you buy Zip shares and sell NextDC shares?

Let's see what one analyst is saying about these popular shares.

Read more »

Two brokers analysing stocks.
Broker Notes

Morgans names 2 ASX shares to buy and 2 to hold

Let's see what the broker is saying about these shares.

Read more »

Hand holding out coal in front of a coal mine.
Broker Notes

Up 379% in 5 years, are Whitehaven Coal shares now a buy, hold or sell?

Here’s what Macquarie is forecasting for Whitehaven Coal shares into 2026.

Read more »

Woman with gold nuggets on her hand.
Broker Notes

Expert tips further upside for this surging ASX 200 gold stock

How much fuel is left in the tank for this gold mining heavyweight?

Read more »

A cute young girl with curly hair sips a glass of milk through a straw with a smile on her face.
Broker Notes

Up 37% this year, why Macquarie expects A2 Milk shares to keep outperforming

Macquarie remains bullish on A2 Milk shares heading into 2026. Let’s see why.

Read more »